Therapy Areas: Respiratory
SpectrumX to Move Forward with the Next Stage in Clinical Development of its Respiratory Drug Candidate SPX-001
25 November 2022 - - UK-based healthcare and pharmaceutical company SpectrumX is prepared to move forward with the next stage in clinical development of its respiratory drug candidate SPX-001 following a constructive scientific advice meeting with the Medicines and Healthcare products Regulatory Agency on Monday, 14th November, the company said.

Per regulatory guidelines, SpectrumX will submit a combined Clinical Trial and Ethics Committee application for a placebo-controlled phase Ib influenza viral challenge study of SPX-001 in healthy volunteers to the MHRA in December 2022.

SPX-001 is SpectrumX's nebulised respiratory infection drug candidate, based on the company's licensed hypochlorous acid -based SPC-069 drug substance, which is believed to have broad-spectrum antipathogenic properties.

If approved, this will the first in-human trial to deliver SPX-001 via a nebulizer to test its efficacy and safety versus a placebo treatment in healthy subjects infected with influenza.

Following successful completion of the planned trial, SpectrumX will move forward with further trials in patients with respiratory infections to gather the additional necessary data for a market authorisation approval.

As previously announced, SpectrumX has already begun the production process for SPX-001, working with a GMP-certified partner, which will accelerate trial-readiness once requisite approvals have been received.

SpectrumX is currently conducting a pre-IPO capital raise in advance of a planned listing on the London Stock Exchange.

SpectrumX is a UK-based healthcare and pharmaceuticals company focused on bringing to market an innovative respiratory infection therapy and the roll-out of the most powerful hand sanitiser in the world to the NHS and other healthcare clients.

Both products utilise unique, patent-pending HOCl formulations.

HOCl is naturally occurring in human white blood cells and is a key contributor in the immune response to infection.

HOCl also has direct killing activity against bacteria, viruses and fungi. It is well-tolerated in humans while also being the most effective known disinfectant when used on surfaces.